Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more
Hikma Pharmaceuticals PLC (HKMPF) - Total Assets
Latest total assets as of June 2025: $5.55 Billion USD
Based on the latest financial reports, Hikma Pharmaceuticals PLC (HKMPF) holds total assets worth $5.55 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hikma Pharmaceuticals PLC - Total Assets Trend (2002–2024)
This chart illustrates how Hikma Pharmaceuticals PLC’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hikma Pharmaceuticals PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Hikma Pharmaceuticals PLC's total assets of $5.55 Billion consist of 44.1% current assets and 55.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.7% |
| Accounts Receivable | $905.00 Million | 17.6% |
| Inventory | $986.00 Million | 19.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $774.00 Million | 15.1% |
| Goodwill | $382.00 Million | 7.4% |
Asset Composition Trend (2002–2024)
This chart illustrates how Hikma Pharmaceuticals PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hikma Pharmaceuticals PLC's current assets represent 44.1% of total assets in 2024, a decrease from 67.9% in 2002.
- Cash Position: Cash and equivalents constituted 3.7% of total assets in 2024, down from 12.8% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 19.2% of total assets.
Hikma Pharmaceuticals PLC Competitors by Total Assets
Key competitors of Hikma Pharmaceuticals PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Hikma Pharmaceuticals PLC - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Hikma Pharmaceuticals PLC generates 0.61x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Hikma Pharmaceuticals PLC generates $6.99 in net profit.
Hikma Pharmaceuticals PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.24 | 1.66 | 1.76 |
| Quick Ratio | 0.72 | 0.98 | 1.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $501.00 Million | $ 905.00 Million | $ 808.00 Million |
Hikma Pharmaceuticals PLC - Advanced Valuation Insights
This section examines the relationship between Hikma Pharmaceuticals PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.90 |
| Latest Market Cap to Assets Ratio | 0.79 |
| Asset Growth Rate (YoY) | 9.7% |
| Total Assets | $5.13 Billion |
| Market Capitalization | $4.04 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hikma Pharmaceuticals PLC's assets below their book value (0.79 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hikma Pharmaceuticals PLC's assets grew by 9.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hikma Pharmaceuticals PLC (2002–2024)
The table below shows the annual total assets of Hikma Pharmaceuticals PLC from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.13 Billion | +9.68% |
| 2023-12-31 | $4.68 Billion | +4.67% |
| 2022-12-31 | $4.47 Billion | +2.26% |
| 2021-12-31 | $4.37 Billion | +5.73% |
| 2020-12-31 | $4.13 Billion | +5.22% |
| 2019-12-31 | $3.93 Billion | +12.38% |
| 2018-12-31 | $3.50 Billion | +3.22% |
| 2017-12-31 | $3.39 Billion | -22.35% |
| 2016-12-31 | $4.36 Billion | +68.00% |
| 2015-12-31 | $2.60 Billion | +15.37% |
| 2014-12-31 | $2.25 Billion | +16.69% |
| 2013-12-31 | $1.93 Billion | +11.50% |
| 2012-12-31 | $1.73 Billion | +9.80% |
| 2011-12-31 | $1.58 Billion | +41.21% |
| 2010-12-31 | $1.12 Billion | +9.10% |
| 2009-12-31 | $1.02 Billion | +5.82% |
| 2008-12-31 | $966.46 Million | +8.10% |
| 2007-12-31 | $894.04 Million | +83.07% |
| 2006-12-31 | $488.36 Million | +22.71% |
| 2005-12-31 | $397.96 Million | +61.46% |
| 2004-12-31 | $246.48 Million | +109.13% |
| 2003-12-31 | $117.86 Million | +24.25% |
| 2002-12-31 | $94.86 Million | -- |